Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
16 Maio 2023 - 9:00AM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced the appointment of Lisa Rojkjaer, M.D., as
Chief Medical Officer. She will serve on the Executive Leadership
team and report to Nathalie Dubois-Stringfellow, Sangamo’s Chief
Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D.,
M.B.A, who is leaving the company to pursue other opportunities. We
thank her for her contributions.
“We are thrilled to welcome Dr. Rojkjaer, an experienced
physician, drug developer, and regulatory expert, to the Sangamo
team,” said Nathalie Dubois-Stringfellow, Chief Development Officer
at Sangamo. “Her deep industry experience across all stages of
clinical development will be pivotal for us as we advance our
wholly owned Fabry program toward a potential Phase 3 trial,
progress our industry-leading CAR-Treg program TX200 through Phase
1/2, and further develop our pre-clinical pipeline of epigenetic
regulation for the central nervous system. Her leadership will be
invaluable as we seek to create targeted potential genomic
medicines for patients suffering from serious genetic diseases for
which there are few or no available treatments today.”
Dr. Rojkjaer brings over 20 years of global and regional
clinical development, regulatory, and medical affairs experience,
as well as an international clinical practice background. She has
held several senior leadership positions in both clinical
development and medical affairs in biotech and global
pharmaceutical companies, having most recently served as Chief
Medical Officer at Viracta Therapeutics. She previously served in
several senior positions focused on the development of small
molecules and biologics for hematology and immunology indications,
including Chief Medical Officer at Nordic Nanovector. Dr. Rojkjaer
was the Global Clinical Program Head at Novartis Oncology, where
she led development and supported the regulatory approval of
Rydapt®. Other previous roles include Chief Medical Officer at
Molecular Partners, and VP, Head of Clinical Development at
MorphoSys AG. Earlier, at Novo Nordisk, she served as Director of
Clinical Development, Hematology in the US and Head, Global Medical
Affairs, Biopharmaceuticals while based in Denmark.
Dr. Rojkjaer holds a Doctor of Medicine degree from the
University of Toronto, where she also completed her internal
medicine and hematology fellowships.
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical
company with a robust genomic medicines pipeline. Using
ground-breaking science, including our proprietary zinc finger
genome engineering technology and manufacturing expertise, Sangamo
aims to create new genomic medicines for patients suffering from
diseases for which existing treatment options are inadequate or
currently don’t exist. To learn more, visit www.sangamo.com and
connect with us on LinkedIn and Twitter.
Sangamo Forward Looking Statements
This press release contains forward-looking statements based on
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to the potential
for Sangamo to create targeted genomic medicines, to advance its
Fabry program toward a Phase 3 trial, to progress its CAR-Treg
program TX200 through Phase 1/2, and to further develop its
pre-clinical pipeline of epigenetic regulation for the central
nervous system. These statements are not guarantees of future
performance and are subject to certain risks and uncertainties that
are difficult to predict. Factors that could cause actual results
to differ include, but are not limited to, the research development
process, including the results of clinical trials; the regulatory
approval process for product candidates; and the potential for
technological developments that obviate technologies used by
Sangamo. Actual results may differ from those projected in
forward-looking statements due to risks and uncertainties that
exist in Sangamo's operations and business. These risks and
uncertainties are described more fully in our Securities and
Exchange Commission filings and reports, including in our Annual
Report on Form 10-K for the year ended December 31, 2022 and our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.
Forward-looking statements contained in this announcement are made
as of this date, and Sangamo undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230516005330/en/
Investor Relations & Media Inquiries Louise Wilkie
ir@sangamo.com media@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024